Partners' Directory

  Home   Search   Join the Partnership   Login

Contact General Specializations in Countries Contribution to the Global Plan Declaration

View this partner's profile

Organization Contact Information

Name: QuantuMDx Group Ltd
Street 1: Lugano Bldg
Street 2: 57 Melbourne St
City: Newcastle upon Tyne
Post Code: NE1 2JQ
Country: United Kingdom of Great Britain and Northern Ireland
Phone: 08708031234
Organization Email:
Web Site:
Other Online Presence:

Focal Point Contact Information

Salutation: Ms
First Name: Debra
Last Name: Daglish
Title: Marketing Communications Manager
Phone: +44 (0) 870 803 1234

Alternate Focal Point Contact Information

Salutation: Dr
First Name: David
Last Name: Dolinger
Title: Vice President, Product Realisation

General Information

Board Constituency: Private sector
Is your organization legally registered in your country: Yes
If yes, please enter your registration number:
Organization Type - Primary: Private Sector
Organization Type - Secondary: Company
Organization Description:
QuantuMDx Group is a multinational technology developer headquartered in the United Kingdom, with operations and partners in the United States, Asia, Europe and Africa.

QuantuMDx is dedicated to improving and democratising global healthcare by developing transformative technologies that will enable rapid, accurate and affordable diagnostic testing in the community.

The company’s flagship product Q-POC’s superior testing capabilities will bring the power of precision medicine to health professionals globally, enabling immediate detection of antimicrobial resistance and subsequent ‘right first time prescribing’in the fight for TB control.

Do you know about the UNHLM declaration:

Specializations / Areas of Work

Provision of drugs, diagnostics and commodities

Other Organization Information

Total number of staff in your organization: 51 - 99
Number of full-time staff who are directly involved with TB: 26 - 50
Number of part-time staff who are directly involved with TB: 0
Number of volunteers who are directly involved with TB: 0
How did you hear about the Stop TB Partnership: Stop TB communications
If you were informed or referred by another partner of the Stop TB Partnership please tell us who:
Why do you wish join the Stop TB Partnership: Information on developments within the TB world
Are you a member of a Stop TB national partnership: No
Are you in contact with your national TB programme: Yes
Please tell us how your organization is contributing to your country's national TB control plan:
We are part of the Innovate UK platform, working on the area of Bovine TB diagnosis.

We are utilising Q-POC's superior multiplexing capability to develop a drug susceptibility test for the future drug regimens. Providing diagnostic tools to fight TB worldwide.

We have also partnered with FIND to overcome the many challenges of sample preparation.

Geographical Reach

Which country is your headquarters located in: United Kingdom of Great Britain and Northern Ireland
Which countries do you do operate in:
(This includes countries you are conducting activities in)
United Kingdom of Great Britain and Northern Ireland
United States of America


Please tell us how your organization will contribute to the Global Plan to Stop TB by briefly describing its involvement in any of the areas of work listed below:

TB Care Delivery:
Q-POC™ will bring molecular diagnostics into microscopy centres, affecting positive change in the community.

Drug-Resistant TB:
Using our handheld molecular diagnostic device, Q-POC™ we will be able to take Drug Sensitivity Testing out of centralized laboratories and into the community. Bringing the power of precision medicine to all, ensuring patients receive the right drug, first time.

New Diagnostics:
Our handheld molecular diagnostic device, Q-POC™ will diagnose the presence and drug resistant status of TB, all in under 10 minutes.

Expected for commercialisation in 2018, Q-POC™ will empower overburdened healthcare systems worldwide with gold standard molecular diagnostics at a fraction of the cost of traditional testing.


Declaration of interests:
No conflicts of interest were delacred.

Application date: March 8, 2016
Last updated: April 30, 2018